You are here: Industry Insights > biologics

News List

Inauguration of the New Richter BioLogics cGMP Facility for the Manufacture of Biopharmaceuticals for the Global Market PharmaSources
October 14, 2024
Richter BioLogics GmbH & Co KG, the microbial biologics affiliate of Gedeon Richter Plc. celebrated the opening of its new cutting-edge biopharmaceutical cGMP facility in Bovenau .
Research Progress on the Application of Biologics in Pediatric Asthma Xiaomichong
July 19, 2024
Asthma is a heterogeneous and complex chronic disease. Children with severe asthma often experience acute exacerbations, ultimately leading to impaired lung function and poor quality of life.
Celonic Inaugurates “Next Generation” Biologics Development Center (BDC) and Pilot Plant in Basel, Switzerland Biotech Newswire
June 24, 2024
The Celonic Group, a Swiss Based Quality Biologics Contract Development and Manufacturing Organization (CDMO) today opened its “Next Generation” Biologics Development Center and Pilot Plant in Basel, Switzerland.
Research Progress on the Application of Biologics in Childhood Asthma. Xiaomichong
October 30, 2023
Asthma is a heterogeneous, complex chronic disease. Children with severe asthma often experience acute exacerbations, leading to impaired lung function and poor quality of life.
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform PRNewswire
January 31, 2025
Telix completes the acquisition from ImaginAb, getting a drug pipeline and a biologics technology platform.
Samsung Biologics presents business updates at 2025 J.P. Morgan Healthcare Conference PRNewswire
January 15, 2025
Samsung Biologics (KRX: 207940.KS) announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan Healthcare Conference, which was held in San Francisco between January 13-16.
Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform PR Newswire
January 13, 2025
Telix Pharma acquires ImaginAb's therapeutic pipeline, tech platform & research facility for innovation boost
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development PRNewswire
January 09, 2025
Samsung Biologics (KRX: 207940.KS) announced to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate (ADC) services.
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab) B3C newswire
November 06, 2023
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
Polpharma Biologics Announces FDA Approval of Tyruko® - First And Only Approved Biosimilar to Tysabri®* for Relapsing Forms of Multiple Sclerosis PharmaSources
August 28, 2023
On August 25, 2023,Polpharma Biologics announced today that the U.S. Food and Drug Administration (FDA) is the first regulatory body worldwide to approve the use of Tyruko®.